Table 6.

Effectiveness of vaccines against variant of concerns of SARS-CoVv-2 strains. The details on name of the vaccines and variants of SARS-CoV-2 concern strains with their references.

Vaccines	Variant of concerns
	B.1.	B.1.1.7	B.1.351	B.1617	P.1
AstraZeneca	66.7% VE [123]	70.4% VE [124]	No protection [125]	59.8% VE [126]	NA
Johnson & Johnson	66.7% VE [127]	NA	64% VE	NA	NA
Pfizer	95% VE [127]	93.4% VE [[126], [127]]	75% VE [127]	87.9% VE [[125], [126], [127], [128]]	Reduction in neutralizing activity [[127], [129]]
Moderna (ADZ1222)	94% VE [127][127]	No significant reduction in neutralizing activity [29]	Significant reduction neutralizing activity [29]	Reduction in neutralizing activity [128]	Reduction in neutralizing activity [127]
Sinopharm	79% VE [127]	Faintly declines the neutralizing activity of vaccine era [130]	Resistance to post vaccination sera with partial reduction in neutralizing activity [130]	NA	NA
Sinovac Biotech	50.7% VE [131]	NA	NA	NA	49.6% VE [131]
BNT162b2	NA	90% VE [132]	75% VE [132]	Reduction in neutralizing activity [[128], [133], [134]][128,133,134]	Neutralizing activity of vaccine era [135]
Ad26.CoV2.S	NA	72% VE [136]	64% VE [136]	Reduction in neutralizing activity [[137], [138]]	64% VE [136]
ChAdOx1 nCoV-19	NA	74% VE [139]	81.5% VE [124][124]	67% VE [139]	81.5% VE [124]
NVX-CoV2373	NA	89.3% VE	49.4% VE [140]	49.4% VE [135]	NA
Covaxin	NA	No reduction [130]	NA	Resistance to neutralizing antibodies [141]	50.4% (symptomatic person) and 78% (asymptomatic person) [142]
Sputnik V	NA	No reduction [143]	Reduction in neutralizing activity [143]	Reduction in neutralizing activity [144]	Reduction in neutralizing activity [145]
BBIBP-CorV	NA	No reduction [143]	No reduction [[130], [143]]	NA	NA
Corona Vac	NA	NA	NA	NA	Reduction in neutralizing activity [[140], [146]]

Abbreviations: NA-not available.